Soleno Therapeutics to Participate in Upcoming September Conferences
Get Alerts SLNO Hot Sheet
Join SI Premium – FREE
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September:
Cantor Global Healthcare Conference
Presentation Date: Wednesday, September 3, 2025 at 1:00 PM ET
Presentation Format: Fireside Chat
Webcast: Here
Wells Fargo Healthcare Conference
Presentation Date: Thursday, September 4, 2025 at 1:30 PM ET
Presentation Format: Fireside Chat
Webcast: Here
H.C. Wainwright 27th Annual Global Investment Conference
Presentation Date: Monday, September 8, 2025 at 4:00 PM ET
Presentation Format: Fireside Chat
Baird Global Healthcare Conference
Presentation Date: Tuesday, September 9, 2025 at 2:00 PM ET
Presentation Format: Fireside Chat
Bernstein 2nd Annual Healthcare Forum
Presentation Date: Thursday, September 25, 2025 at 9:40 AM ET
Presentation Format: Fireside Chat
Replays of the Cantor and Wells Fargo events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
Source: Soleno Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto News: Remittix Announces $0.46 Final Price Ahead of Its Market Debut as BNB Price Prediction Targets $1,500
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
- Remittix Price Prediction: Official Launch Date and PayFi Utility Put the $5 RTX Debate Back on the Table
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Robert W Baird, Sanford C. Bernstein, Wells Fargo, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share